EGFR and non-small cell lung carcinoma: For example, gefitinib (Iressa) and erlotinib (Tarceva), two drugs inhibiting epidermal growth factor receptor (EGFR) tyrosine kinase, are effective therapies for non-small cell lung cancer (NSCLC) [2]–[4].